176 related articles for article (PubMed ID: 24365161)
1. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI
Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161
[TBL] [Abstract][Full Text] [Related]
2. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
3. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR
J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026
[TBL] [Abstract][Full Text] [Related]
4. Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.
Anand JP; Purington LC; Pogozheva ID; Traynor JR; Mosberg HI
Chem Biol Drug Des; 2012 Nov; 80(5):763-70. PubMed ID: 22882801
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain.
Nastase AF; Griggs NW; Anand JP; Fernandez TJ; Harland AA; Trask TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
ACS Chem Neurosci; 2018 Jul; 9(7):1840-1848. PubMed ID: 29677442
[TBL] [Abstract][Full Text] [Related]
6. Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.
Purington LC; Sobczyk-Kojiro K; Pogozheva ID; Traynor JR; Mosberg HI
ACS Chem Biol; 2011 Dec; 6(12):1375-81. PubMed ID: 21958158
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
[TBL] [Abstract][Full Text] [Related]
8. Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands.
Harland AA; Bender AM; Griggs NW; Gao C; Anand JP; Pogozheva ID; Traynor JR; Jutkiewicz EM; Mosberg HI
J Med Chem; 2016 May; 59(10):4985-98. PubMed ID: 27148755
[TBL] [Abstract][Full Text] [Related]
9. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW
Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222
[TBL] [Abstract][Full Text] [Related]
10. Mu and Delta Opioid Receptors Are Coexpressed and Functionally Interact in the Enteric Nervous System of the Mouse Colon.
DiCello JJ; Carbone SE; Saito A; Rajasekhar P; Ceredig RA; Pham V; Valant C; Christopoulos A; Veldhuis NA; Canals M; Massotte D; Poole DP
Cell Mol Gastroenterol Hepatol; 2020; 9(3):465-483. PubMed ID: 31759144
[TBL] [Abstract][Full Text] [Related]
11. Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.
Purington LC; Pogozheva ID; Traynor JR; Mosberg HI
J Med Chem; 2009 Dec; 52(23):7724-31. PubMed ID: 19788201
[TBL] [Abstract][Full Text] [Related]
12. Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.
Milan-Lobo L; Whistler JL
J Pharmacol Exp Ther; 2011 Jun; 337(3):868-75. PubMed ID: 21422164
[TBL] [Abstract][Full Text] [Related]
13. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
[TBL] [Abstract][Full Text] [Related]
14. Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.
Henry SP; Fernandez TJ; Anand JP; Griggs NW; Traynor JR; Mosberg HI
J Med Chem; 2019 Apr; 62(8):4142-4157. PubMed ID: 30924650
[TBL] [Abstract][Full Text] [Related]
15. Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.
Henry S; Anand JP; Twarozynski JJ; Brinkel AC; Pogozheva ID; Sears BF; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2020 Feb; 63(4):1671-1683. PubMed ID: 31986033
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activities.
Hu M; Giulianotti MA; McLaughlin JP; Shao J; Debevec G; Maida LE; Geer P; Cazares M; Misler J; Li L; Dooley C; Ganno ML; Eans SO; Mizrachi E; Santos RG; Yongye AB; Houghten RA; Yu Y
Eur J Med Chem; 2015 Mar; 92():270-81. PubMed ID: 25559207
[TBL] [Abstract][Full Text] [Related]
17. Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy.
Harland AA; Pogozheva ID; Griggs NW; Trask TJ; Traynor JR; Mosberg HI
ACS Chem Neurosci; 2017 Nov; 8(11):2549-2557. PubMed ID: 28796483
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing agonist potency and selectivity for the opioid delta receptor are revealed in structure-activity relationship studies of the 4-[(N-substituted-4-piperidinyl)arylamino]-N,N-diethylbenzamides.
Thomas JB; Herault XM; Rothman RB; Atkinson RN; Burgess JP; Mascarella SW; Dersch CM; Xu H; Flippen-Anderson JL; George CF; Carroll FI
J Med Chem; 2001 Mar; 44(6):972-87. PubMed ID: 11300879
[TBL] [Abstract][Full Text] [Related]
19. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
[TBL] [Abstract][Full Text] [Related]
20. Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor.
Margolis EB; Fujita W; Devi LA; Fields HL
Neuropharmacology; 2017 Sep; 123():420-432. PubMed ID: 28645621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]